Brinda Balakrishnan Net Worth

The estimated Net Worth of Brinda Balakrishnan is at least $117 millier dollars as of 21 May 2024. Brinda Balakrishnan owns over 520 units of Aurinia Pharmaceuticals Inc stock worth over $114,425 and over the last 3 years Brinda sold AUPH stock worth over $2,985.

Brinda Balakrishnan AUPH stock SEC Form 4 insiders trading

Brinda has made over 2 trades of the Aurinia Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Brinda sold 520 units of AUPH stock worth $2,985 on 21 May 2024.

The largest trade Brinda's ever made was exercising 8,733 units of Aurinia Pharmaceuticals Inc stock on 18 May 2023 worth over $57,026. On average, Brinda trades about 2,313 units every 92 days since 2021. As of 21 May 2024 Brinda still owns at least 17,523 units of Aurinia Pharmaceuticals Inc stock.

You can see the complete history of Brinda Balakrishnan stock trades at the bottom of the page.

What's Brinda Balakrishnan's mailing address?

Brinda's mailing address filed with the SEC is #140, 14315 - 118 AVENUE, , EDMONTON, A0, T5L 4S6.

Insiders trading at Aurinia Pharmaceuticals Inc

Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden et Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.

What does Aurinia Pharmaceuticals Inc do?

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Complete history of Brinda Balakrishnan stock trades at Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc executives and stock owners

Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Peter Greenleaf,
  President, Chief Executive Officer, Director
• Peter S. Greenleaf M.B.A.,
  Pres, CEO & Director
• Maxwell Donley,
  Executive Vice President, Internal Operations & Strategy
• Neil Solomons,
  Chief Marketing Officer
• Massimiliano Colao,
  Chief Commercial Officer
• Robert Huizinga,
  Executive Vice President - Corporate Development
• Matthew Maxwell Donley M.B.A.,
  Exec. VP of Operations & Strategy
• Joseph M. Miller CPA,
  Chief Financial Officer
• Dennis Bourgeault,
  Chief Financial Officer
• Michael Martin,
  Chief Operating Officer
• Daniel Billen,
  Director
• George Milne,
  Independent Chairman of the Board
• Michael Hayden,
  Independent Director
• Stephen P. Robertson,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Joseph Hagan,
  Independent Director
• David Jayne,
  Independent Director
• R. Hector MacKay-Dunn,
  Director
• Jill Leversage,
  Independent Director
• Stephen Robertson,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Timothy Walbert,
  Independent Director
• Max Colao,
  Chief Commercial Officer
• Tim Hermes,
  Vice President of Market Access
• Cara Felish,
  Vice President of Commercial Operations
• Chris Hays,
  Vice President of Marketing
• Fran Lynch,
  Vice President of Sales
• Glenn Schulman,
  Senior Vice President - Corporate Communications and Investor Relations
• Michael R. Martin,
  Chief Bus. Officer
• Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
  Exec. VP of Research
• Scott Michael Habig,
  Chief Commercial Officer
• Volker Knappertz,
  EVP, Research and Development
• Joseph M Miller,
  Chief Financial Officer
• Brinda Balakrishnan,
  Director
• Robert T Foster,
  Director
• Massimilano Colao,
  Chief Commercial Officer
• Jeffrey Allen Bailey,
  Director
• Karen L. Smith,
  Director